CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immix Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immix Biopharma Inc
11400 West Olympic Blvd., Suite 200
Phone: (310) 651-8041p:310 651-8041 LOS ANGELES, CA  90064  United States Ticker: IMMXIMMX
Business Summary
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer IlyaRachman 52 1/1/2012 1/1/2012
Scientific Co-Founder VladimirTorchilin 77 1/1/2012 1/1/2012
Chief Financial Officer, Director GabrielMorris 38 3/1/2021 3/1/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
IMMIX BIOPHARMA AUSTRALIA PTY LTD COLLINGWOOD AU

Business Names
Business Name
Australia Pty Ltd.
Immix Biopharma
Immix Biopharma Australia Pty Ltd.
IMMX
Nexcella, Inc.
Organization or

General Information
Number of Employees: 18 (As of 3/11/2025)
Outstanding Shares: 27,722,108 (As of 3/11/2025)
Shareholders: 28
Stock Exchange: NASD
Federal Tax Id: 454869378


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025